Unassociated Document

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

DATE OF REPORT - December 22, 2006

(Date of Earliest Event Reported)

COLUMBIA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File No. 1-10352

Delaware		59-2758596
(State of Incorporation)		(I.R.S. Employer Identification No.)

354 Eisenhower Parkway Livingston, New Jersey		07039
(Address of principal executive offices)		Zip Code

Registrant’s telephone number, including area code: (973) 994-3999

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On December 22, 2006, Columbia Laboratories, Inc. (the “Company”), issued a press release entitled, “Columbia Laboratories Completes Treatment Phase of Phase III Study of Prochieve 8% to Prevent Recurrent Preterm Birth.” A copy of the press release issued by the Company is filed herewith as Exhibit 99.1.

The information furnished herewith pursuant to Item 7.01 of this Current Report and in Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The furnishing of such information is not an admission as to the materiality of any of the information set forth therein or herein. The information in this Item 7.01 and in Exhibit 99.1 hereto shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On December 22, 2006, the Company issued a press release entitled, “Columbia Laboratories to Raise $40 Million through Private Placement of Convertible Subordinated Notes; Company will use Proceeds to Buy U.S. Marketing Rights to CRINONE® Progesterone Gel.” A copy of the press release issued by the Company is filed herewith as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits

99.1

Press Release dated December 22, 2006, entitled “Columbia Laboratories Completes Treatment Phase of Phase III Study of Prochieve 8% to Prevent Recurrent Preterm Birth.”

99.2

Press Release dated December 22, 2006, entitled “Columbia Laboratories to Raise $40 Million through Private Placement of Convertible Subordinated Notes; Company will use Proceeds to Buy U.S. Marketing Rights to CRINONE® Progesterone Gel.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 22, 2006

	COLUMBIA LABORATORIES, INC.
	By	/S/ James Meer
	James Meer
	Senior Vice President, Chief Financial Officer
	and Treasurer

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated December 22, 2006, entitled “Columbia Laboratories Completes Treatment Phase of Phase III Study of Prochieve 8% to Prevent Recurrent Preterm Birth.”
99.2	Press Release dated December 22, 2006, entitled “Columbia Laboratories to Raise $40 Million through Private Placement of Convertible Subordinated Notes; Company will use Proceeds to Buy U.S. Marketing Rights to CRINONE® Progesterone Gel.”